Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

被引：53
作者：
Verstockt, Bram [1 ,2 ]
Noor, Nurulamin M. [3 ,4 ]
Marigorta, Urko M. [5 ,6 ]
Pavlidis, Polychronis [7 ,8 ]
Deepak, Parakkal [9 ]
Ungaro, Ryan C. [10 ]
机构：
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Katholieke Univ Leuven, Translat Res Ctr Gastrointestinal Disorders TARGI, Dept Chron Dis & Metab, Leuven, Belgium
[3] Cambridge Univ Hosp NHS Trust, Addenbrookes Hosp, Dept Gastroenterol, Cambridge, England
[4] UCL, Med Res Council Clin Trials Unit, London, England
[5] Ctr Cooperat Res Biosci CIC bioGUNE, Integrat Genom Lab, Basque Res & Technol Alliance BRTA, Derio, Spain
[6] Basque Fdn Sci, Ikerbasque, Bilbao, Spain
[7] Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol, London, England
[8] Kings Coll London, Sch Immunol & Microbial Sci, London, England
[9] Washington Univ, Sch Med, Inflammatory Bowel Dis Ctr, St Louis, MO USA
[10] Icahn Sch Med Mt Sinai, Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷 / 09期
关键词：
Precision medicine; personalised medicine; inflammatory bowel diseases; disease prognosis; disease outcome; response to therapy; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; PERSONALIZED MEDICINE; PREDICTS RESPONSE; FOLLOW-UP; ASSOCIATION; INFLIXIMAB; EXPRESSION; BIOMARKERS; DAMAGE;
D O I：
10.1093/ecco-jcc/jjab050
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.
引用
收藏
页码：1431 / 1442
页数：12
相关论文
共 113 条
  • [1] Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial
    Adams, Richard
    Brown, Ewan
    Brown, Louise
    Butler, Rachel
    Falk, Stephen
    Fisher, David
    Kaplan, Richard
    Quirke, Phil
    Richman, Susan
    Samuel, Leslie
    Seligmann, Jenny
    Seymour, Matt
    Shiu, Kai Keen
    Wasan, Harpreet
    Wilson, Richard
    Maughan, Tim
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (03) : 162 - 171
  • [2] Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases
    Aden, Konrad
    Rehman, Ateequr
    Waschina, Silvio
    Pan, Wei-Hung
    Walker, Alesia
    Lucio, Marianna
    Nunez, Alejandro Mena
    Bharti, Richa
    Zimmerman, Johannes
    Bethge, Johannes
    Schulte, Berenice
    Schulte, Dominik
    Franke, Andre
    Nikolaus, Susanna
    Schroeder, Johann Oltmann
    Vandeputte, Doris
    Raes, Jeroen
    Szymczak, Silke
    Waetzig, Georg H.
    Zeuner, Rainald
    Schmitt-Kopplin, Philippe
    Kaleta, Christoph
    Schreiber, Stefan
    Rosenstiel, Philip
    [J]. GASTROENTEROLOGY, 2019, 157 (05) : 1279 - +
  • [3] Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
    Alsoud, Dahham
    Vermeire, Severine
    Verstockt, Bram
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2020, 55 : 17 - 30
  • [4] Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases
    Ananthakrishnan, Ashwin N.
    Luo, Chengwei
    Yajnik, Vijay
    Khalili, Hamed
    Garber, John J.
    Stevens, Betsy W.
    Cleland, Thomas
    Xavier, Ramnik J.
    [J]. CELL HOST & MICROBE, 2017, 21 (05) : 603 - +
  • [5] Adaptive platform trials: definition, design, conduct and reporting considerations The Adaptive Platform Trials Coalition
    Angus, Derek C.
    Alexander, Brian M.
    Berry, Scott
    Buxton, Meredith
    Lewis, Roger
    Paoloni, Melissa
    Webb, Steven A. R.
    Arnold, Steven
    Barker, Anna
    Berry, Donald A.
    Bonten, Marc J. M.
    Brophy, Mary
    Butler, Christopher
    Cloughesy, Timothy F.
    Derde, Lennie P. G.
    Esserman, Laura J.
    Ferguson, Ryan
    Fiore, Louis
    Gaffey, Sarah C.
    Gaziano, J. Michael
    Giusti, Kathy
    Goossens, Herman
    Heritier, Stephane
    Hyman, Bradley
    Krams, Michael
    Larholt, Kay
    LaVange, Lisa M.
    Lavori, Philip
    Lo, Andrew W.
    London, Alex John
    Manax, Victoria
    McArthur, Colin
    O'Neill, Genevieve
    Parmigiani, Giovanni
    Perlmutter, Jane
    Petzold, Elizabeth A.
    Ritchie, Craig
    Rowan, Kathryn M.
    Seymour, Christopher W.
    Shapiro, Nathan, I
    Simeone, Diane M.
    Smith, Bradley
    Spellberg, Bradley
    Stern, Ariel Dora
    Trippa, Lorenzo
    Trusheim, Mark
    Viele, Kert
    Wen, Patrick Y.
    Woodcock, Janet
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (10) : 797 - 807
  • [6] Biomarker-guided trials: Challenges in practice
    Antoniou, M.
    Kolamunnage-Dona, R.
    Wason, J.
    Bathia, R.
    Billingham, C.
    Bliss, J. M.
    Brown, L. C.
    Gillman, A.
    Paul, J.
    Jorgensen, A. L.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
  • [7] Antoniou M, 2017, BIOMARKER GUIDED TRI
  • [8] Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
    Antoniou, Miranta
    Jorgensen, Andrea L.
    Kolamunnage-Dona, Ruwanthi
    [J]. PLOS ONE, 2016, 11 (02):
  • [9] Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
    Arijs, I.
    Li, K.
    Toedter, G.
    Quintens, R.
    Van Lommel, L.
    Van Steen, K.
    Leemans, P.
    De Hertogh, G.
    Lemaire, K.
    Ferrante, M.
    Schnitzler, F.
    Thorrez, L.
    Ma, K.
    Song, X. -Y R.
    Marano, C.
    Van Assche, G.
    Vermeire, S.
    Geboes, K.
    Schuit, F.
    Baribaud, F.
    Rutgeerts, P.
    [J]. GUT, 2009, 58 (12) : 1612 - 1619
  • [10] Predictive Value of Epithelial Gene Expression Profiles for Response to Infliximab in Crohn's Disease
    Arijs, Ingrid
    Quintens, Roel
    Van Lommel, Leentje
    Van Steen, Kristel
    De Hertogh, Gert
    Lemaire, Katleen
    Schraenen, Anica
    Perrier, Clementine
    Van Assche, Gert
    Vermeire, Severine
    Geboes, Karel
    Schuit, Frans
    Rutgeerts, Paul
    [J]. INFLAMMATORY BOWEL DISEASES, 2010, 16 (12) : 2090 - 2098
12345678910